Evaluation of an antineoplastic agent. Dactinomycin (Cosmegen).
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Thirty-three patients with malignant nondysgerminomatous germ cell tumors were treated with vincristine/dactinomycin/cyclophosphamide regimen. Thirty-two patients were suitable for analysis. The overall cure rate was 68.7%. This is comparable to the cure rate observed in the cisplatin/vinblastin/bleomycin regimen. The roles of second-look laparotomy in malignant germ cell tumor are discussed.
Explore the source record for details and available documents.